In a report released yesterday, Chris Cooley from Stephens reiterated a Buy rating on Steris Corp (NYSE: STE), with a price target of $125. The company’s shares closed yesterday at $113.39, close to its 52-week high of $117.48.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 34.4% and a 75.0% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Staar Surgical Company, and DENTSPLY SIRONA Inc.
Steris Corp has an analyst consensus of Moderate Buy, with a price target consensus of $119.50.
See today’s analyst top recommended stocks >>
Based on Steris Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $69.99 million. In comparison, last year the company had a net profit of $58.08 million.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STERIS Plc engages in the provision of infection prevention and other procedural products and services. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies.
